Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. [PDF]
Violante-Ortiz R +5 more
europepmc +1 more source
Stereotypes and Discrimination Toward Weight Loss Injection Users
ABSTRACT Background GLP‐1 receptor agonists such as semaglutide and tirzepatide are increasingly prescribed for weight loss and prevention of obesity‐related diseases. Although effective, users are likely to face stigma, as medication‐based weight loss is often perceived as less legitimate than lifestyle changes.
Philipp Sprengholz, Maike Klöckner
wiley +1 more source
The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. [PDF]
Trott M +4 more
europepmc +1 more source
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso +7 more
wiley +1 more source
Facial nodules following filler injections after initiating compounded tirzepatide use. [PDF]
Luke M, Kara H, Angela M.
europepmc +1 more source
Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents. [PDF]
Knackstedt LA.
europepmc +1 more source
Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report. [PDF]
van der Walle EEPL +3 more
europepmc +1 more source
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes. [PDF]
Shloush M +3 more
europepmc +1 more source
Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement. [PDF]
Li Z +7 more
europepmc +1 more source

